ID: h-a40b5598
Hypothesis
BET Bromodomain Inhibition for Neuroinflammation Suppression
BET Bromodomain Inhibition for Neuroinflammation Suppression.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 4 oppose
🧪 Overview
BET Bromodomain Inhibition for Neuroinflammation Suppression
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["BRD4 Reader<br/>Bromo and ET Domains"]
B["Acetyl-Lysine Recognition<br/>Histone Tail Binding"]
C["P-TEFb Release<br/>CDK9 Cyclin T1 Activation"]
D["RNA Pol II Elongation<br/>Super-Enhancer Targets"]
E["c-MYC Upregulation<br/>Proliferative Gene Expression"]
F["NFKB Pathway<br/>Pro-inflammatory Transcriptional Program"]
G["BRD4 Inhibition<br/>JQ1 or OTX015 Treatment"]
H["Anti-inflammatory Effect<br/>Pro-survival Gene Suppression"]
I["Tau Pathology<br/>Kinase Regulation"]
J["Neuronal Death<br/>BRD4-Driven Vulnerability"]
A --> B
B --> C
C --> D
D --> E
D --> F
F --> H
G --> H
G -.->|"reduces"| E
F --> I
I --> J
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style J fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix5 supports4 contradicts
Supports
BRD4 occupancy at inflammatory gene promoters correlates with H3K27ac in AD microglia
Supports
BET inhibitor JQ1 reduces neuroinflammation and improves survival in ALS mouse models
Supports
Pan-BET inhibition shows favorable brain penetration and anti-inflammatory effects in neurodegeneration models
Supports
ABBV-744 shows improved selectivity for BD4 over BD2/3, potentially reducing class-effect toxicities
Contradicts
BBB penetration suboptimal - JQ1 has poor pharmaceutical properties for chronic CNS dosing
Contradicts
BRD4 regulates activity-dependent gene expression critical for synaptic plasticity and memory - broad inhibition could impair cognitive function in AD patients
Contradicts
Chronic BET inhibition causes thrombocytopenia and immune suppression as class effects
Contradicts
Inflammation is not universally detrimental - microglial surveillance functions could be impaired
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — BRD4
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for BRD4 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BRD4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0013
Events (7d)
1
Price History
▼2.8%💾 Resource Usage
LLM Tokens
34,738
$0.1042
Total Cost
$0.1042
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF iPSC-derived microglia from sporadic Alzheimer's disease patients are treated with JQ1 (500 nM) for 48 hours following LPS stimulation (100 ng/mL), THEN secreted IL-6 and CXCL10 concentrations in c | ≥50% reduction in IL-6 and CXCL10 secretion from JQ1-treated microglia | — no observation — | pending | 0.48 |
| IF C57BL/6 mice receive daily intraperitoneal JQ1 (50 mg/kg) starting 24 hours after MPTP injection for 21 days, THEN striatal TNF-α and IL-1β protein levels will decrease by ≥40% compared to vehicle- | ≥40% reduction in striatal pro-inflammatory cytokines (TNF-α, IL-1β) with JQ1 treatment | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF C57BL/6 mice receive daily intraperitoneal JQ1 (50 mg/kg) starting 24 hours after MPTP injection for 21 days, THEN striatal TNF-α and IL-1β protein levels will decrease by ≥40% compared to vehicle-treated mice within 4 weeks of treatment initiation.
Predicted outcome: ≥40% reduction in striatal pro-inflammatory cytokines (TNF-α, IL-1β) with JQ1 treatment
Falsification: Striatal TNF-α and IL-1β levels show no statistically significant reduction (p > 0.05) or reduction <40% compared to vehicle controls, measured by ELISA
pendingconf 48%
IF iPSC-derived microglia from sporadic Alzheimer's disease patients are treated with JQ1 (500 nM) for 48 hours following LPS stimulation (100 ng/mL), THEN secreted IL-6 and CXCL10 concentrations in conditioned media will decrease by ≥50% compared to DMSO-treated cells within 72 hours of treatment.
Predicted outcome: ≥50% reduction in IL-6 and CXCL10 secretion from JQ1-treated microglia
Falsification: IL-6 or CXCL10 concentrations show no statistically significant reduction (p > 0.05) or reduction <50% compared to DMSO controls, measured by multiplex immunoassay
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.